<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03063879</url>
  </required_header>
  <id_info>
    <org_study_id>96-04-37-37348</org_study_id>
    <nct_id>NCT03063879</nct_id>
  </id_info>
  <brief_title>Treating Hepatitis C in CRF Using Sofosbuvir and Daclatasvir</brief_title>
  <acronym>SD-CRF</acronym>
  <official_title>Efficacy and Safety of Sofosbuvir and Daclatasvir in Treating Patients With Hepatitis C and Renal Failure.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tehran University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ahvaz Jundishapur University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shiraz University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hamadan University of Medical Science</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Tehran University of Medical Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Sofosbuvir is the base of most treatment regimens for hepatitis C. In patients with renal
      failure the blood level of one of its metabolites (GS-331007) rises up to 20 folds. Although
      no particular adverse event has been linked to this metabolite sofosbuvir is not recommended
      for patients with renal failure mainly because of lack of data. Nevertheless there are
      anecdotal reports and small studies proving the safety of sofosbuvir in renal failure. This
      study addresses this lack of information by evaluating the safety and efficacy of sofosbuvir
      and daclatasvir in treating hepatitis C in 200 patients with renal failure.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 1, 2017</start_date>
  <completion_date type="Anticipated">September 1, 2018</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sustained Viral Response (SVR12)</measure>
    <time_frame>12 weeks after end of treatment</time_frame>
    <description>Lack of detectable hepatitis C virus in blood 12 weeks after end of treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety as assessed by adverse drug events</measure>
    <time_frame>From start of treatment to 12 weeks after end of treatment</time_frame>
    <description>Adverse drug events recorded by direct questioning</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">200</enrollment>
  <condition>Hepatitis C, Chronic</condition>
  <condition>Chronic Renal Failure</condition>
  <arm_group>
    <arm_group_label>Sovodak</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sofosbuvir 400 mg and daclatasvir 60 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sofosbuvir 400 mg and daclatasvir 60 mg</intervention_name>
    <description>Daily fixed dose combination pill (Sovodak) containing 400 mg sofosbuvir and 60 mg daclatasvir for 12 weeks if not cirrhotic (liver stiffness &lt; 12 KPa) or 24 weeks if cirrhotic</description>
    <arm_group_label>Sovodak</arm_group_label>
    <other_name>Sovodak</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Positive qualitative hepatitis C virus RNA test on two occasions at least 6 months
             apart

          -  Renal failure (eGFR &gt; 30 cc/min)

        Exclusion Criteria:

          -  Model for End-stage Liver Disease (MELD) score &gt; 20,

          -  Child's C (CTP score &gt; 12),

          -  Heart rate &lt; 50/min,

          -  Taking amiodarone
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shahin Merat, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tehran University of Medical Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Shariati Hospital</name>
      <address>
        <city>Tehran</city>
        <zip>14117</zip>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 21, 2017</study_first_submitted>
  <study_first_submitted_qc>February 23, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 24, 2017</study_first_posted>
  <last_update_submitted>April 27, 2018</last_update_submitted>
  <last_update_submitted_qc>April 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hepatitis C</keyword>
  <keyword>renal failure</keyword>
  <keyword>sofosbuvir</keyword>
  <keyword>daclatasvir</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sofosbuvir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

